Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/29637
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | TAMURA, Rodrigo Esaki | |
dc.contributor.author | LUNA, Igor Vieira de | |
dc.contributor.author | LANA, Marlous Gomes | |
dc.contributor.author | STRAUSS, Bryan E. | |
dc.date.accessioned | 2018-11-21T17:09:08Z | |
dc.date.available | 2018-11-21T17:09:08Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | CLINICS, v.73, suppl.1, article ID UNSP e476s, 7p, 2018 | |
dc.identifier.issn | 1807-5932 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/29637 | |
dc.description.abstract | Gene therapy has been evaluated for the treatment of prostate cancer and includes the application of adenoviral vectors encoding a suicide gene or oncolytic adenoviruses that may be armed with a functional transgene. In parallel, versions of adenoviral vector expressing the p53 gene (Ad-p53) have been tested as treatments for head and neck squamous cell carcinoma and non-small cell lung cancer. Although Ad-p53 gene therapy has yielded some interesting results when applied to prostate cancer, it has not been widely explored, perhaps due to current limitations of the approach. To achieve better functionality, improvements in the gene transfer system and the therapeutic regimen may be required. We have developed adenoviral vectors whose transgene expression is controlled by a p53-responsive promoter, which creates a positive feedback mechanism when used to drive the expression of p53. Together with improvements that permit efficient transduction, this new approach was more effective than the use of traditional versions of Ad-p53 in killing prostate cancer cell lines and inhibiting tumor progression. Even so, gene therapy is not expected to replace traditional chemotherapy but should complement the standard of care. In fact, chemotherapy has been shown to assist in viral transduction and transgene expression. The cooperation between gene therapy and chemotherapy is expected to effectively kill tumor cells while permitting the use of reduced chemotherapy drug concentrations and, thus, lowering side effects. Therefore, the combination of gene therapy and chemotherapy may prove essential for the success of both approaches. | |
dc.description.sponsorship | Sao Paulo Research Foundation, FAPESP [2011/21256-8, 2016/18197-3, 2012/05066-7, 2013/25167-5, 2015/26580-9] | |
dc.description.sponsorship | CNPQ [442738/2014-5] | |
dc.language.iso | eng | |
dc.publisher | HOSPITAL CLINICAS, UNIV SAO PAULO | |
dc.relation.ispartof | Clinics | |
dc.rights | openAccess | |
dc.subject | Prostate Cancer | |
dc.subject | Adenovirus | |
dc.subject | p53 | |
dc.subject | Chemotherapy | |
dc.subject | Gene Therapy | |
dc.subject.other | wild-type p53 | |
dc.subject.other | cell lung-cancer | |
dc.subject.other | phase-i trial | |
dc.subject.other | recurrent ovarian-cancer | |
dc.subject.other | term-follow-up | |
dc.subject.other | recombinant adenovirus | |
dc.subject.other | replication-competent | |
dc.subject.other | oncolytic adenovirus | |
dc.subject.other | clinical-trial | |
dc.subject.other | mediated p53 | |
dc.title | Improving adenoviral vectors and strategies for prostate cancer gene therapy | |
dc.type | article | |
dc.rights.holder | Copyright HOSPITAL CLINICAS, UNIV SAO PAULO | |
dc.identifier.doi | 10.6061/clinics/2018/e476s | |
dc.identifier.pmid | 30133562 | |
dc.subject.wos | Medicine, General & Internal | |
dc.type.category | review | |
dc.type.version | publishedVersion | |
hcfmusp.description.articlenumber | UNSP e476s | |
hcfmusp.description.issue | suppl 1 | |
hcfmusp.description.volume | 73 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.id | WOS:000684065500009 | |
hcfmusp.origem.id | 2-s2.0-85055506106 | |
hcfmusp.origem.id | SCIELO:S1807-59322018000200309 | |
hcfmusp.publisher.city | SAO PAULO | |
hcfmusp.publisher.country | BRAZIL | |
hcfmusp.relation.reference | Agell L, 2008, MODERN PATHOL, V21, P1470, DOI 10.1038/modpathol.2008.145 | |
hcfmusp.relation.reference | [Anonymous], 2003, BIODRUGS, V17, P216 | |
hcfmusp.relation.reference | Armstrong Cameron M, 2015, Am J Clin Exp Urol, V3, P64 | |
hcfmusp.relation.reference | Asgari K, 1997, INT J CANCER, V71, P377, DOI 10.1002/(SICI)1097-0215(19970502)71:3<377::AID-IJC13>3.0.CO;2-D | |
hcfmusp.relation.reference | Atencio IA, 2006, CANCER GENE THER, V13, P169, DOI 10.1038/sj.cgt.7700870 | |
hcfmusp.relation.reference | Azab BM, 2014, J CELL PHYSIOL, V229, P34, DOI 10.1002/jcp.24408 | |
hcfmusp.relation.reference | Azarenko O, 2014, MOL CANCER THER, V13, P2092, DOI 10.1158/1535-7163.MCT-14-0265 | |
hcfmusp.relation.reference | Bajgelman MC, 2008, VIROLOGY, V371, P8, DOI 10.1016/j.virol.2007.11.015 | |
hcfmusp.relation.reference | Bettendorf O, 2008, GENE CHROMOSOME CANC, V47, P565, DOI 10.1002/gcc.20560 | |
hcfmusp.relation.reference | Brooks JD, 1996, CANCER RES, V56, P3814 | |
hcfmusp.relation.reference | Buller RE, 2002, CANCER GENE THER, V9, P553, DOI 10.1038/sj.cgt.7700472 | |
hcfmusp.relation.reference | Buller RE, 2002, CANCER GENE THER, V9, P567, DOI 10.1037/sj.cgt.7700473 | |
hcfmusp.relation.reference | Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497 | |
hcfmusp.relation.reference | Chandrasekar T, 2015, TRANSL ANDROL UROL, V4, P365, DOI 10.3978/j.issn.2223-4683.2015.05.02 | |
hcfmusp.relation.reference | Chappell WH, 2012, CELL CYCLE, V11, P4579, DOI 10.4161/cc.22852 | |
hcfmusp.relation.reference | Cheng WS, 2006, CANCER GENE THER, V13, P13, DOI 10.1038/sj.cgt.7700881 | |
hcfmusp.relation.reference | Cmielova J, 2015, FOLIA BIOL-PRAGUE, V61, P60 | |
hcfmusp.relation.reference | Dagher R, 2004, CLIN CANCER RES, V10, P8147, DOI 10.1158/1078-0432.CCR-04-1402 | |
hcfmusp.relation.reference | Das K, 2005, CLIN GENET, V68, P40, DOI 10.1111/j.1399-0004.2005.00452.x | |
hcfmusp.relation.reference | de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X | |
hcfmusp.relation.reference | Dean JL, 2013, CURR DRUG TARGETS, V14, P460 | |
hcfmusp.relation.reference | Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178 | |
hcfmusp.relation.reference | Debruyne Frans, 2002, Semin Urol Oncol, V20, P4, DOI 10.1053/suro.2002.35051 | |
hcfmusp.relation.reference | DeWeese TL, 2001, CANCER RES, V61, P7464 | |
hcfmusp.relation.reference | Don M, 2008, J INT MED RES, V36, P1273 | |
hcfmusp.relation.reference | EASTHAM JA, 1995, CANCER RES, V55, P5151 | |
hcfmusp.relation.reference | Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210 | |
hcfmusp.relation.reference | Freytag SO, 2002, CANCER RES, V62, P4968 | |
hcfmusp.relation.reference | Freytag SO, 2003, CANCER RES, V63, P7497 | |
hcfmusp.relation.reference | Freytag SO, 2007, MOL THER, V15, P1016, DOI 10.1038/mt.sj.6300120 | |
hcfmusp.relation.reference | Freytag SO, 2007, MOL THER, V15, P636, DOI 10.1038/sj.mt.6300068 | |
hcfmusp.relation.reference | Fujiwara T, 2006, J CLIN ONCOL, V24, P1689, DOI 10.1200/JCO.2005.03.4116 | |
hcfmusp.relation.reference | Galletti E, 2007, CHEMMEDCHEM, V2, P920, DOI 10.1002/cmdc.200600308 | |
hcfmusp.relation.reference | Galletti G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6548 | |
hcfmusp.relation.reference | Ganansia-Leymarie Valerie, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P291, DOI 10.2174/1568011033482422 | |
hcfmusp.relation.reference | Gjerset R, 2001, METH MOL B, V175, P495 | |
hcfmusp.relation.reference | Guan YS, 2009, J ZHEJIANG UNIV-SC B, V10, P331, DOI 10.1631/jzus.B0820248 | |
hcfmusp.relation.reference | Hazlehurst LA, 1999, CANCER RES, V59, P1021 | |
hcfmusp.relation.reference | Heidenreich A, 2014, NAT REV UROL, V11, P189, DOI 10.1038/nrurol.2014.36 | |
hcfmusp.relation.reference | Herman JR, 1999, HUM GENE THER, V10, P1239, DOI 10.1089/10430349950018229 | |
hcfmusp.relation.reference | Horio Y, 2000, CANCER GENE THER, V7, P537, DOI 10.1038/sj.cgt.7700148 | |
hcfmusp.relation.reference | Hwang C, 2012, THER ADV MED ONCOL, V4, P329, DOI 10.1177/1758834012449685 | |
hcfmusp.relation.reference | Inoue A, 2000, CANCER LETT, V157, P105, DOI 10.1016/S0304-3835(00)00480-8 | |
hcfmusp.relation.reference | KAPUSCINSKI J, 1986, P NATL ACAD SCI USA, V83, P6302, DOI 10.1073/pnas.83.17.6302 | |
hcfmusp.relation.reference | KAPUSCINSKI J, 1985, BIOCHEM PHARMACOL, V34, P4203, DOI 10.1016/0006-2952(85)90275-8 | |
hcfmusp.relation.reference | KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059 | |
hcfmusp.relation.reference | Kluth M, 2014, INT J CANCER, V135, P1369, DOI 10.1002/ijc.28784 | |
hcfmusp.relation.reference | Ko SC, 1996, HUM GENE THER, V7, P1683, DOI 10.1089/hum.1996.7.14-1683 | |
hcfmusp.relation.reference | Kosaka T, 2011, J UROLOGY, V185, P2376, DOI 10.1016/j.juro.2011.02.016 | |
hcfmusp.relation.reference | Kraaij R, 2007, PROSTATE, V67, P829, DOI 10.1002/pros.20560 | |
hcfmusp.relation.reference | Kuball J, 2002, J CLIN ONCOL, V20, P957, DOI 10.1200/JCO.20.4.957 | |
hcfmusp.relation.reference | Kumon H, 2015, CTS-CLIN TRANSL SCI, V8, P837, DOI 10.1111/cts.12362 | |
hcfmusp.relation.reference | Lane DP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001222 | |
hcfmusp.relation.reference | Latham JPF, 2000, CANCER RES, V60, P334 | |
hcfmusp.relation.reference | Lee SJ, 2002, MOL THER, V6, P415, DOI 10.1006/mthe.2002.0682 | |
hcfmusp.relation.reference | Leroy B, 2013, NUCLEIC ACIDS RES, V41, pD962, DOI 10.1093/nar/gks1033 | |
hcfmusp.relation.reference | Li X, 2008, CLIN CANCER RES, V14, P291, DOI 10.1158/1078-0432.CCR-07-0867 | |
hcfmusp.relation.reference | Li Y, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-16 | |
hcfmusp.relation.reference | Li YM, 2002, J UROLOGY, V167, P339, DOI 10.1016/S0022-5347(05)65465-1 | |
hcfmusp.relation.reference | Li ZL, 2016, ACTA PHARMACOL SIN, V37, P1121, DOI 10.1038/aps.2016.59 | |
hcfmusp.relation.reference | Liu CF, 2013, PROSTATE, V73, P418, DOI 10.1002/pros.22583 | |
hcfmusp.relation.reference | Lu YS, 2013, ABSTR APPL ANAL, DOI 10.1155/2013/247307 | |
hcfmusp.relation.reference | Lubaroff DM, 2014, IMMUNOL RES, V59, P229, DOI 10.1007/s12026-014-8531-2 | |
hcfmusp.relation.reference | Lubaroff DM, 2009, CLIN CANCER RES, V15, P7375, DOI 10.1158/1078-0432.CCR-09-1910 | |
hcfmusp.relation.reference | Miettinen S, 2009, ANTI-CANCER DRUG, V20, P589, DOI 10.1097/CAD.0b013e32832dad3d | |
hcfmusp.relation.reference | Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3 | |
hcfmusp.relation.reference | Nasu Y, 2007, MOL THER, V15, P834, DOI 10.1038/mt.sj.6300096 | |
hcfmusp.relation.reference | Nguyen TV, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2015.21 | |
hcfmusp.relation.reference | Ning X, 2011, CANCER GENE THER, V18, P444, DOI 10.1038/cgt.2011.15 | |
hcfmusp.relation.reference | Nishizaki M, 2001, CLIN CANCER RES, V7, P2887 | |
hcfmusp.relation.reference | Paller CJ, 2011, DRUG DES DEV THER, V5, P117, DOI 10.2147/DDDT.S13029 | |
hcfmusp.relation.reference | Peng ZH, 2005, HUM GENE THER, V16, P1016, DOI 10.1089/hum.2005.16.1016 | |
hcfmusp.relation.reference | Pisters LL, 2004, CLIN CANCER RES, V10, P2587, DOI 10.1158/1078-0432.CCR-03-0388 | |
hcfmusp.relation.reference | Poeta ML, 2007, NEW ENGL J MED, V357, P2552, DOI 10.1056/NEJMoa073770 | |
hcfmusp.relation.reference | Radhakrishnan S, 2010, HUM GENE THER, V21, P1311, DOI 10.1089/hum.2010.019 | |
hcfmusp.relation.reference | Rojas-Martinez A, 2013, CANCER GENE THER, V20, P642, DOI 10.1038/cgt.2013.56 | |
hcfmusp.relation.reference | Rong BX, 2016, SCI REP-UK, V6, DOI 10.1038/srep39355 | |
hcfmusp.relation.reference | Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985 | |
hcfmusp.relation.reference | Ryan CJ, 2006, UROL ONCOL-SEMIN ORI, V24, P396, DOI 10.1016/j.urolonc.2005.09.003 | |
hcfmusp.relation.reference | Schuler M, 1998, HUM GENE THER, V9, P2075, DOI 10.1089/hum.1998.9.14-2075 | |
hcfmusp.relation.reference | Schuler M, 2001, J CLIN ONCOL, V19, P1750, DOI 10.1200/JCO.2001.19.6.1750 | |
hcfmusp.relation.reference | Seth P, 1997, CANCER GENE THER, V4, P383 | |
hcfmusp.relation.reference | Shen YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147173 | |
hcfmusp.relation.reference | Shi CX, 2002, HUM GENE THER, V13, P211, DOI 10.1089/10430340252769743 | |
hcfmusp.relation.reference | Shirakawa T, 2007, HUM GENE THER, V18, P1225, DOI 10.1089/hum.2007.074 | |
hcfmusp.relation.reference | Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387 | |
hcfmusp.relation.reference | Singh J, 2010, CLIN INTERV AGING, V5, P187 | |
hcfmusp.relation.reference | Small EJ, 2006, MOL THER, V14, P107, DOI 10.1016/j.ymthe.2006.02.011 | |
hcfmusp.relation.reference | Sonpavde G, 2011, CLIN CANCER RES, V17, P7174, DOI 10.1158/1078-0432.CCR-11-1899 | |
hcfmusp.relation.reference | Strauss BE, 2005, CANCER GENE THER, V12, P935, DOI 10.1038/sj.cgt.7700846 | |
hcfmusp.relation.reference | Strauss BE, 2004, VIROLOGY, V321, P165, DOI 10.1016/j.virol.2003.12.021 | |
hcfmusp.relation.reference | Tamura RE, 2017, HUM GENE THER, V28, P639, DOI 10.1089/hum.2016.139 | |
hcfmusp.relation.reference | Tamura RE, 2016, CANCER BIOL THER, V17, P1221, DOI 10.1080/15384047.2016.1235655 | |
hcfmusp.relation.reference | Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720 | |
hcfmusp.relation.reference | Teply BA, 2016, INDIAN J UROL, V32, P262, DOI 10.4103/0970-1591.191239 | |
hcfmusp.relation.reference | Vrignaud P, 2014, DRUG DES DEV THER, V8, P1851, DOI 10.2147/DDDT.S64940 | |
hcfmusp.relation.reference | Wang GX, 2012, J INT MED RES, V40, P317, DOI 10.1177/147323001204000132 | |
hcfmusp.relation.reference | WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045 | |
hcfmusp.relation.reference | WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079 | |
hcfmusp.relation.reference | Wonganan P, 2009, CANCER GENE THER, V16, P405, DOI 10.1038/cgt.2008.99 | |
hcfmusp.relation.reference | Wu L, 2001, GENE THER, V8, P1416, DOI 10.1038/sj.gt.3301549 | |
hcfmusp.relation.reference | Xiao JE, 2017, ONCOL LETT, V13, P3676, DOI 10.3892/ol.2017.5901 | |
hcfmusp.relation.reference | Xiong L, 2007, CLIN CANCER RES, V13, P5463 | |
hcfmusp.relation.reference | Yamanaka K, 2005, MOL CANCER THER, V4, P187 | |
hcfmusp.relation.reference | YANG CL, 1995, CANCER RES, V55, P4210 | |
hcfmusp.relation.reference | Yang YF, 2014, GENE THER, V21, P723, DOI 10.1038/gt.2014.46 | |
hcfmusp.relation.reference | Yoo GH, 2010, AM J OTOLARYNG, V31, P78, DOI 10.1016/j.amjoto.2008.10.002 | |
hcfmusp.relation.reference | Yoo GH, 2004, LARYNGOSCOPE, V114, P1871, DOI 10.1097/01.mlg.0000147914.51239.ed | |
hcfmusp.relation.reference | Yu DC, 2001, CANCER RES, V61, P517 | |
hcfmusp.relation.reference | Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947 | |
hcfmusp.relation.reference | ZHANG WW, 1994, CANCER GENE THER, V1, P5 | |
dc.description.index | MEDLINE | |
dc.identifier.eissn | 1980-5322 | |
hcfmusp.citation.scopus | 8 | |
hcfmusp.scopus.lastupdate | 2024-03-28 | |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/ICESP Artigos e Materiais de Revistas Científicas - LIM/24 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_TAMURA_Improving_adenoviral_vectors_and_strategies_for_prostate_cancer_2018.PDF | publishedVersion (English) | 373.3 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.